Frozen Eggs
By Tom Ashbrook,
NPR On Point
| 10. 26. 2012
[With CGS's Marcy Darnovsky]
Women freezing their eggs against future infertility – or, as a lifestyle choice. We’ll look at the science and its limits.
For most of history, when women were out of eggs they were out of luck when it came to reproducing, to bearing children. Then came the freezing of human eggs. Formally for women facing fertility-damaging medical treatment. For couples in fertility treatment.
But also, it turned out, for women getting older who just weren’t ready pregnancy. Didn’t have the right partner, the right job, the right circumstances. So they’d freeze some eggs. For when the time came.
This hour, On Point: women freezing their eggs against future infertility. How far does this go?
Guests
Samantha Pfeifer, associate professor of Obstetrics and Gynecology at the University of Pennsylvania.
Marcy Darnovsky, associate executive director of the Center for Genetics and Society.
Jennifer Hayes, a woman who has frozen her eggs.
From Tom’s Reading List
Wall Street Journal “There is growing evidence suggesting that freezing an embryo after fertilization and thawing it for use in the woman’s next...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...